BACKGROUND: Magnesium (Mg) has been used as an adjuvant medication in postoperative analgesia. We planed this study to assess the effects of Mg, when added to lidocaine in intravenous regional anesthesia (IVRA) on the tourniquet pain.
ntravenous regional anesthesia (IVRA) is one of the safest and most consistent modes of regional anesthesia for short procedures on upper extremity. 1 In spite of this, it has been limited by tourniquet pain, 2 and lack of ability to offer postoperative analgesia. [3] [4] [5] The best IVRA solution should have the following characteristics: fast onset, low dose of local anesthetic, decreased tourniquet pain, and extended postdeflation analgesia. 6 Right now, this may merely be reached by adding adjuncts to local anesthetics with limited accomplishment. 6 The use of magnesium (Mg) as an adjuvant in perioperative analgesia is unique. The double blind prospective study of Tramer et al. obviously demonstrated the value of Mg as an adjuvant in postoperative analgesia. 7 Magnesium has been revealed to be doing well in reducing pain related with injection of propofol 8 and rocuronium. 9 In a different study by Turan and colleagues, 10 adding magnesium to lidocaine in IVRA revealed diminished intraoperative fentanyl use and pain associated with the tourniquet. Turan's study was the first one on this issue. However, the authors emphasized that more studies should be carried out to determine a relevant conclusion before its regular use. So, we designed the present study, as a second one to assess the effects of magnesium when added to lidocaine in IVRA.
Methods
Forty ASA physical status I and II patients, aged 20-65 year old, listed for elective hand surgery gave formal, written consent to take part in this randomized double-blind study, which was approved by our local commission on human being investigation. They were planned to undertake either carpal tunnel release, removal of a ganglion cyst, or tenolysis. Patients with Raynaud's disease, sickle cell anemia, or a history of allergy to any drug were excluded from the study. A randomization list was created. Identical syringes, full of drugs were prepared by Certified Registered Nurse Anesthetist (CRNA) blinded to the study. Once the patients were transferred to the operating room, mean arterial blood pressure (MAP), peripheral oxygen saturation (Spo2), and heart rate (HR) were monitored. Before setting up the anesthetic block, two cannulae were placed; one was in a vein on the dorsum of the operative hand and the other in the contrary hand for crystalloid infusion. The operative arm was raised for 3 minutes then, exsanguinated with an Esmarch bandage. A pneumatic tourniquet was left all-around the upper arm, and the proximal cuff was inflated to 250 mmHg. Circulatory isolation of the arm was confirmed by inspection, lack of radial pulse, and failure of pulse oximetry tracing of the ipsilateral index finger. IVRA was accomplished using 20 ml lidocaine 1% diluted with 20 ml saline to a total of 40 ml in the group L (n = 20) or 7.5 ml magnesium sulfate 20% plus 20 ml lidocaine 1% diluted with 12.5 ml saline to a total of 40 ml in the group M (n = 20). The mixture was introduced in more than 90 seconds by an anesthesiologist blinded to the injected drug. The sensory block was evaluated by a pinprick executed with a 22-gauge shortbeveled needle pulled out constantly each 30 seconds. Patient response was assessed in the dermatomal sensory distribution of the medial and lateral antebrachial cutaneous, ulnar, median, and radial nerves. Motor function was judged by asking the subject to flex and extend his/her wrist and fingers, and complete motor block was documented when no voluntary movement was achievable. Sensory block onset time was noted as the time passed from injection of study drug to sensory block completed the entire dermatomes. Motor block onset time was the time passed by from introduction of study drug to perfect motor block. Subsequent to accomplishment of sensory and motor blocks, the distal cuff was inflated to 250 mmHg followed by release of the proximal tourniquet; the surgery was then begun. MAP, HR, and Spo2 were monitored before and after tourniquet use, at 5, 10, 15, 20, 30, 40, and 50 minutes after the beginning of anesthesia. Hypotension (25% decrease in blood pressure from the baseline value) was treated with IV ephedrine (3 to 10 mg bolus). Bradycardia (25% decrease in HR from the baseline value) was treated with IV atropine, 0.5 mg. Arterial oxygen saturation < 91% was treated with O2 supplementation delivered through a facemask. Evaluation of tourniquet pain scores was achieved on the basis of the visual analog scale (VAS) (0 = "no pain" and 10 = "worst pain imaginable") 10,11 determined before and after tourniquet use, at 5, 10, 15, 20, 30, 40, and 50 minutes after the injection of anesthetic medication. Intraoperatively, boluses of 1Dg/kg fentanyl were supplied for tourniquet pain treatment at any necessary time (when VAS > 4), and sum of fentanyl consumptions was recorded. After the operation, the surgeon, who was not aware of given medication, was inquired to qualify the operative situation consistent with the following numeric scale: 1 = unsuccessful, 2 = poor, 3 = acceptable and 4 = perfect. At the conclusion of operation, the quality of the operative condition was assessed along with subsequent numeric scale: 4 (excellent) = no complaint from the patient, 3 (good) = minor complaint with no need for supplemental analgesics, 2 (moderate) = complaint that required supplemental analgesics, and 1 (unsuccessful) = patient given general anesthesia. The tourniquet was not deflated earlier than 30 minutes and was not inflated for more than 1.5 hours. At the end of surgery, the tourniquet deflation was made by cyclic deflation method. Sensory recovery time was noticed (time passed by after tourniquet deflation up to the recovery of pain in all dermatomes ascertained by pinprick test). Motor block recovery time was recorded (the time elapsed from tourniquet deflation until movement of fingers). The first analgesic requirement time was also noted (the time elapsed from tourniquet release until the first patient demand for analgesic drug). Evaluation of postoperative pain was completed on the basis of the VAS. MAP, HR, and VAS values were recorded at 6, 12, and 24 hours. Patients received 0.1 mg IV morphine when VAS > 4. Full amounts of morphine administration to each group were recorded. Through the study period, any local or systemic complications including nausea, vomiting, skin rash, tachycardia, bradycardia, hypotension, hypertension, headache, dizziness, tinnitus, hypoxemia, sedation, respiratory depression, bradypnea, tachypnea, and other side effects were noted. The statistical evaluation was performed using SPSS version 11.0. Independent samples t-test was used for evaluation of the demographic data, intraoperative or postoperative hemodynamic data, the time of the onset or recovery of sensory and motor blocks, the duration of the operation and tourniquet, and intraoperative or postoperative analgesic use. Mann-Whitney U-test was used for intraoperative and postoperative VAS. The quality of the anesthesia was analyzed by using G² and Fisher's exact tests. A P value < 0.05 was considered significant.
Results
Forty patients consented to take part in the study. The two groups were comparable with respect to demographic characteristics. There was no significant difference in tourniquet time, duration of anesthesia or surgery between the two groups (table 1). There was no statistically significant difference between the two groups for MAP, HR or Spo2 at any time during the study. The onset of sensory or motor block was significantly shorter in group M compared with group L (P < 0.05) (table 2). Sensory or motor block recovery time was more prolonged in group M compared with group L but it was not statistically significant (table 2) . Intraoperative VAS scores were significantly lower in group M compared with group L at 20, 30, 40, and 50 minutes after tourniquet inflation (P < 0.05) (table 3). Fentanyl requirement was significantly lower in group M compared with group L (P < 0.05) (table 2). Number of patients who needed additional fentanyl administration was significantly less in group M compared with group L (10/20 vs. 18/20 respectively, P < 0.05). Anesthesia quality, as determined by the anesthesiologist and the surgeon, was significantly better in group M (P < 0.01) (table 4). The time to the first patients' request for morphine administration after surgery was significantly prolonged in group M compared with group L (53.75 ± 6.94 minutes vs. 40.76 ± 14.55 respectively, P < 0.05). Postoperative VAS scores were significantly lower at 6 , 12, and 24 hours after surgery in group M compared with group L (P < 0.05) (table 5). Postoperative morphine consumption (mean ± SD) was less at 6, 12, and 24 hours in group M compared with group L but it was not statistically significant (2.0 ± 0.6 vs. 3.5 ± 2.4 mg; 0.0 ± 0.0 vs. 0.5 ± 0.3 mg; 0.0 ± 0.0 vs. 0.5 ± 0.3 mg; P > 0.05). There was no significant adverse effect during the 24-hour postoperative periods in either group. www.SID.ir Table 5 . Postoperative VAS scores. 
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Discussion
Our study showed that adding magnesium to lidocaine for IVRA enhances the speed of onset and the quality of anesthesia, decreases tourniquet pain and intraoperative analgesic use, lengthens the time to the first patients' demand for morphine administration after surgery, and finally, does not produce significant side effects. This claim is based on the antagonist properties of Mg for the NMDA receptor and its inhibitory properties for calcium channels. 7 Calcium channel blockers have revealed antinociceptive effects in animals and morphine potentiation in patients with chronic pain. NMDA receptor antagonists can inhibit the induction of central sensitization owing to peripheral nociceptive stimulation and eliminate hypersensitivity 7 . Tramer and Glynn 12 used magnesium for the treatment of chronic limb pain in IVRA and showed that the addition of magnesium to lidocaine increases the quality of the block, lengthens the analgesia, and decreases the overall failure rate. The double blind prospective study of Tramer et al clearly showed the value of Mg as an adjuvant in postoperative analgesia. Tramer and colleagues demonstrated that patients getting Mg as an adjuvant in postoperative analgesia, needed less morphine, had fewer distresses and slept better through the first 48 hours than those receiving morphine alone. The quality of postoperative analgesia was, certainly, the same. Three respiratory depressions occurred in the controlled analgesia group receiving morphine only vs. no one in the group treated by morphine and Mg. 7 Koinig et al described similar results with a decreasing analgesic use both intra-and post-operatively in the group receiving Mg pre-and intra-operatively. 13 In both studies, plasma Mg concentration was markedly diminished postoperatively in the control group (values close to hypomagnesemia), but was significantly raised in the treatment group. 7, 13 Wilder-Smith et al 14 carried out a comparative study of pain intensity and postoperative use of morphine in three groups. In each group, patients received ketamine, Mg or fentanyl pre-and intraoperatively. No differences were demonstrated between groups for the effects of these products.
In an additional statement, Mg infusion after anesthesia induction decreased intraoperative consumption of remifentanil. 15 In two other studies, the tendency in the direction of reduced use of fentanyl intraoperatively 16 and morphine postoperatively 16, 17 was verified, but showed no statistically significant difference.
In the study of Wilder-Smith et al, 17 lack of significance was most likely owing to the small numbers of patients in the groups. Moreover, magnesium possesses an endothelium-derived nitric oxide-induced vasodilatory effect. 18, 19 The pneumatic tourniquet produces ischemia, which interferes with nerve dissemination by oxidative stress and influences the blood-nerve barrier. 20 Nitric oxide donors have been demonstrated to defend vascular endothelium from ischemia/reperfusion-mediated endothelial dysfunction. 21 In the present study, in contrast to Turan et al 10 study in which postoperative VAS scores were significantly higher for only the first 6 hours postoperatively in control group compared with magnesium group, postoperative VAS scores were significantly lower at 6, 12, and 24 hours after surgery in group M compared with group L. This difference between the two studies may be due to dissimilarity in severity of insults to the hand and techniques of surgery. Also, in our study, we used 20 ml lidocaine 1% in both groups regardless of the precise body weight and it is probable that we overestimated the lidocaine dosage in some patients. This was a limitation of our study. In our study, the sensory and motor block recovery times were not different in the two groups www.SID.ir while in Turan et al study, these variables were statistically prolonged in group receiving magnesium and lidocaine. This difference between the results of the two studies may also be due to over-or under-estimation of lidocaine dosage in both groups. In summary, adding magnesium to lidocaine in IVRA demonstrated reduced intraoperative fentanyl use and pain associated with the tourniquet. It also shortened sensory and motor block onset times and made better the quality of anesthesia while prolonged the time to the first postoperative analgesic requirement. The addition of magnesium to a local anesthetic in IVRA was effective; nevertheless, more studies must be carried out with further peripheral techniques and several doses to establish an appropriate conclusion before its regular use.
